In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Applied DNA Sciences (APDN – Research Report), with a price target of $3.00. The company’s shares opened today at $1.39.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Achieve Life Sciences, and Oncolytics Biotech. According to TipRanks, McCarthy has an average return of -27.4% and a 24.24% success rate on recommended stocks.
Applied DNA Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $4.00, implying a 187.77% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.
See today’s best-performing stocks on TipRanks >>
APDN market cap is currently $18.33M and has a P/E ratio of -3.31.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Applied DNA Sciences, Inc. engages in the provision of security solutions. It offers molecular-based technology solutions and services that can help protect products, brands, supply chains, and intellectual property of companies, governments, and consumers from theft, counterfeiting, fraud, and diversion. Its products include the following brands: Applied DNA Sciences, SigNature, molecular tags, SigNature, T molecular tags, fiberTyping, DNAnet, digitalDNA, SigNify, BackTrac, Beacon, and CertainT. The company was founded in 1983 and is headquartered in Stony Brook, NY.
Read More on APDN:
